A post-hoc analysis, recently presented during the annual meeting of the European Association for the Study of Diabetes, has demonstrated that Xultophy significantly reduced a number of risk factors associated with CVD in diabetic patients Read more


Novo Nordisk has announced that CHMP has adopted a positive opinion for Xultophy, the first ever once-daily basal insulin and GLP-1 analogue in one pen. Read more